What really happens when tirzepatide and vitamin B12 are mixed in the same vial?
In this deep dive, we break down the science behind Eli Lilly’s recent warning and preprint, which identified a previously unknown tirzepatide-B12 molecular complex in compounded samples, in some cases making up a significant portion of the vial. The analysis also revealed major potency variation, with some products testing far below their labelled strength.
But the real question isn’t just what was found, it’s what it actually means.
We explore:
how and why molecules interact differently in a shared vial vs the human body
what Lilly’s analytical data proves, and what it doesn’t
why formulation conditions (pH, concentration, solvent) can drive structural change
and how theoretical risks like aggregation and immunogenicity should be interpreted
This episode separates chemical possibility from clinical reality, and explains why understanding where interactions occur is key to understanding whether they matter at all.
Comments